Leen Kawas is a renowned scientist and entrepreneur who has significantly contributed significantly to biotechnology. She is currently the CEO of Propel Bio, a biotech company focused on developing therapies for rare diseases.
Kawas has an impressive academic background, earning a Ph.D. in pharmacy from the University of Jordan and a Master’s in Business Administration from the University of California, Irvine. She has also published several research papers and is a recognized speaker at various industry conferences.

Before joining Propel Bio, Kawas held several leadership positions in various biotech companies, including Avid Bioservices, Laguna Pharmaceuticals, and MabVax Therapeutics. Her drug development and commercialization expertise have helped these companies achieve significant milestones and establish themselves as key players in the biotech industry.

At Propel Bio, Leen Kawas has driven the company’s growth and success. Under her leadership, the company has secured significant funding and formed strategic partnerships with leading pharmaceutical companies. Propel Bio is developing several novel therapies for rare diseases, including sickle cell disease and beta-thalassemia.

Besides her professional achievements, Leen Kawas also advocates for diversity and inclusion in the workplace. She has been recognized as a leader in this area and has received several awards for promoting gender equality and diversity in the biotech industry.

Leen Kawas is a highly accomplished biotech executive who has made significant contributions to the industry. Her leadership and expertise have helped Propel Bio become a leading player in rare disease therapeutics, and her commitment to diversity and inclusion inspires others in the industry.